Detection of an EGFR L858R mutation following prolonged sequential ALK-TKI therapy in ALK-rearranged NSCLC: a case report
Anaplastic lymphoma kinase ( ALK )-rearranged non-small cell lung cancer (NSCLC) typically exhibits profound sensitivity to ALK tyrosine kinase inhibitors (TKIs). While sequential therapy with next-generation inhibitors has significantly improved long-term outcomes, acquired resistance remains an eventual challen...